Hybrid lipid nanoparticles and uses thereof
A lipid nanoparticle composition with oxidized lipids and PEI, using cell-derived lipids and pH-responsive PEI conjugates, addresses immune activation issues in conventional LNPs, improving safety and delivery efficiency for immunocompromised patients.
Patent Information
- Application Number
- PCT/US2026/027661
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional lipid nanoparticle (LNP) systems trigger immune recognition and immune inflammation, limiting their use in chronic therapies, especially in immunocompromised patients due to synthetic lipid formulations activating immune pathways through TLR4/NF-KB signaling.
A lipid nanoparticle composition comprising oxidized lipids and polyethylene imine (PEI), where PEI is either electrostatically or covalently bonded to the lipid, with optional integration of gold nanoparticles for enhanced cellular uptake and theranostic applications, using lipids extracted from mammalian cells to mimic native lipid signatures and reduce immunogenicity.
The composition reduces immune recognition and cytotoxicity, enhancing delivery efficiency and safety for immunocompromised patients by leveraging cell-specific lipids and pH-responsive PEI conjugates for endosomal escape.
Smart Images

Figure US2026027661_19112026_PF_FP_ABST
Abstract
Description
[0001] Atty Docket No. 60247-442119 HYBRID LIPID NANOPARTICLES AND USES THEREOF
[0002] RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 804,238, filed May 12, 2025, the entire disclosure of which is incorporated herein by reference.
[0004] BACKGROUND
[0005] The COVID-19 pandemic demonstrated the importance of lipid nanoparticles (LNPs) as fundamental components for gene and drug delivery systems. Conventional LNP systems face several limitations: synthetic lipid formulations often trigger immune recognition, limiting their utility in chronic therapies which restrict their use in long-term treatments. Recent studies show that small differences in synthetic LNPs and host cell membrane lipids can activate immune pathways through TLR4 / NF-KB signaling which leads to immune inflammation and clearance problems in immunocompromised patients. Accordingly, advances in LNP compositions are needed.
[0006] SUMMARY
[0007] In one aspect, the present disclosure relates to a lipid nanoparticle (LNP) composition comprising a lipid-PEI nanoparticle comprising an oxidized lipid and a polyethylene imine (PEI). In some embodiments, the PEI is electrostatically complexed to the lipid. In some embodiments, the PEI is covalently bonded to the lipid. In some embodiments, the PEI comprises an ionizable amine.
[0008] In another aspect, the present disclosure relates to a process for preparing a lipid nanoparticle (LNP) composition as described herein. In some embodiments, the process comprises:
[0009] (a) extracting lipids from a sample comprising a cell population; and
[0010] (b) contacting the lipids (i.e., extracted lipids) with a polyethylene imine polymer (PEI), thereby forming a lipid-PEI nanoparticle.
[0011] In another aspect, the present disclosure relates to a lipid nanoparticle (LNP) composition prepared according to the process as described herein.
[0012] In another aspect, the present disclosure relates to a method of treating a disease in a patient in need thereof, the method comprising administering a therapeutically effective amount of the LNP composition as described herein.Atty Docket No. 60247-442119 In another aspect, the present disclosure relates to a method of transfecting a cell, the method comprising contacting the cell with an effective amount of the LNP composition as described herein.
[0013] In another aspect, the present disclosure relates to a method of imaging a cell, the method comprising contacting the cell with an effective amount of the LNP composition as described herein.
[0014] BRIEF DESCRIPTIONS OF THE DRAWING
[0015] Fig. 1 shows a process for extracting lipids from a blood sample or from cell culture. Figs. 2A-D show a comparison of transfecting plasmid DNA with LNP compositions of the present disclosure (LNP6) including a fluorescent marker cargo of compared to a commercially available transfection agent. Fig. 2A shows the commercial agent transfection results from an immunofluorescence assay with the fluorescence image (top left) and the light image (bottom left) compared to the LNP compositions of the present disclosure with the fluorescence image (top right) and the light image (bottom right). Fig. 2B shows a representative experimental design of a Fluorescence-Activated Cell Sorting (FACS) assay using flow cytometry. Fig. 2C shows the flow cytometry results with an FSC-A vs SSC-A dot plot indicating the gated cell population (top left), and histograms of the control (top right) compared to the commercial agent (bottom left) and the LNP of the present disclosure (bottom right). Fig. 2D shows the quantification of GFP (+) cells from Fig. 2C.
[0016] Fig. 3 shows the effect of arginine conjugation to the PEI with the (+) arginine PEI containing LNP composition (LNP5) on the left (top fluorescence, bottom light) and the (-) arginine PEI LNP composition (LNP18) on the right (top fluorescence, bottom light).
[0017] Figs. 4A-B show transfecting mRNA in cells with LNP compositions of the present disclosure (LNP6). Fig. 4A shows the transfection of an mRNA encoding green fluorescent protein (GFP) in HEK 293 cells with the fluorescence image (right) and the light image (left). Fig. 4B shows the transfection of an mRNA encoding GFP in fibroblasts with the fluorescence image (left) and the light image (right).
[0018] Figs. 5A-B show LNP compositions of the present disclosure (LNP5) including gold nanoparticles and Alexa Fluor™ 555 dye encapsulated within the LNPs. Fig. 5A shows LNP-gold NP uptake in HEK 293 cells after two hours with light image (left) and fluorescence image (right). Fig. 5B shows LNP-gold NP uptake in HEK 293 cells after four hours with light image (left) and fluorescence image (right).Atty Docket No. 60247-442119 Fig. 6 shows fluorescence microscopy images in fibroblast cells treated with LNP composition (LNP5) encapsulating Alexa Fluor™ 555 dye without gold nanoparticles (left) and with gold nanoparticles (right).
[0019] Fig. 7 shows trypan blue uptake in HEK 293 cells using LNP compositions of the present disclosure (LNP6).
[0020] Fig. 8 shows images from the encapsulation of trypan blue (a gold-standard dye for live / dead staining that normally cannot cross the membrane of live cells) into the LNP compositions of the present disclosure (LNP 13).
[0021] Fig. 9 shows images from the encapsulation of red fluorescent protein (RFP) plasmid DNA into LNPs having PEI-2000 (a positively charged component) conjugated with histidine using EDC / NHS chemistry. LNPs with different PEI to imidazole / histidine ratios were tested (LNPs 11-15).
[0022] Fig. 10 shows agarose gel electrophoresis with several lipid nanoparticles (LNPs) with different cationic or ionizable charge properties. Compositions were V249 (LNP5) & V315 (LNP6) (PEI- Arginine), and V316 (LNP11, PEI-Histidine).
[0023] DETAILED DESCRIPTION
[0024] Before the present disclosure is further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended clauses.
[0025] For the sake of brevity, the disclosures of the publications cited in this specification, including patents, are herein incorporated by reference. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entireties. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in a patent, application, or other publication that is herein incorporated by reference, the definition set forth in this section prevails over the definition incorporated herein by reference.
[0026] As used herein and in the appended clauses, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the clauses may be drafted to exclude any optional element. As such, this statement is intended toAtty Docket No. 60247-442119 serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of clause elements, or use of a “negative” limitation.
[0027] As used herein, the terms “including,” “containing,” and “comprising” are used in their open, non-limiting sense.
[0028] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.
[0029] Except as otherwise noted, the methods and techniques of the present embodiments are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Loudon, Organic Chemistry, Fourth Edition, New York: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001.
[0030] Chemical nomenclature for compounds described herein has generally been derived using the commercially-available ACD / Name 2014 (ACD / Labs) or ChemBioDraw Ultra 13.0 (Perkin Elmer).
[0031] As used herein and in connection with chemical structures depicting the various embodiments described herein, and " < "each represent a point of covalent attachment of the chemical group or chemical structure in which the identifier is shown to an adjacent chemical group or chemical structure. For example, in a hypothetical chemical structure A-B, where A and B are joined by a covalent bond, in some embodiments, the portion of A-B "A *" "A
[0032]
[0033] defined by the group or chemical structure A can be represented by , , or "A — _L
[0034]
[0035] ’ , where each of and “ ” represents a bond to A and the point of covalent bond attachment to B. Alternatively, in some embodiments, the portion of A-B defined
[0036]
[0037] _ gn n _ gn b g»» by the group or chemical structure B can be represented by , , or
[0038] , where each of
[0039]
[0040] and “ represents a bond to B and the point of covalent bond attachment to A.Atty Docket No. 60247-442119 It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the chemical groups represented by the variables are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub-combination of chemical groups was individually and explicitly disclosed herein.
[0041] DEFINITIONS
[0042] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.
[0043] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N.Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed ”, W. H. Freeman & Co., N.Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed ”, Sinauer Associates, Inc., Sunderland, Mass. (2000).
[0044] Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, Calif. (1985).
[0045] All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.Atty Docket No. 60247-442119 To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about.” It is understood that, whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and / or measurement conditions for such given value. For example, the term “about” may be an approximation of ± 10%, ±5%, or ±1%. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.
[0046] The term “agent” is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known.
[0047] A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
[0048] The term “patient-derived,” such as a patient-derived sample or patient-derived cells, refers to a biological material, such as (tumor) tissue, cells, blood, or fluids, obtained directly from a patient.
[0049] “Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. As used herein, and as well understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.Atty Docket No. 60247-442119 The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and / or clinically significant amount.
[0050] “Administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0051] Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and / or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
[0052] As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.Atty Docket No. 60247-442119 A “therapeutically effective amount” or a “therapeutically effective dose” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. The precise effective amount needed for a subject will depend upon, for example, the subject's size, health and age, and the nature and extent of the condition being treated, such as cancer. The skilled worker can readily determine the effective amount for a given situation by routine experimentation.
[0053] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not.
[0054] It is understood that substituents and substitution patterns on the compounds of the present disclosure can be selected by one of ordinary skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
[0055] The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
[0056] The term “derivative” refers to a compound formed from or related to the parent compound to which it refers. A derivative of a compound is chemically modified by the modification or substitution of an atom or group of atoms.
[0057] The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0058] It will be understood that the chemical entities described herein, can exist as a salt of a free acid or base of a compound represented herein and an inorganic or organic counter ion. Illustratively, the salt can be formed during the manufacture of the compound (e.g., a salt or a pharmaceutically acceptable salt) or can substituted to a salt for further manufacture, formulation, or administration reasons. As illustrated herein, certain compounds include a “W® ,” wherein “W® ” is an inorganic counter ion (e.g., an inorganic anion) or an organic counter ion (e.g., anAtty Docket No. 60247-442119 organic anion). In certain embodiments, W® is an anion that is complexed with a cation of a compound of the disclosure to form a pharmaceutically acceptable salt.
[0059] “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.
[0060] The term “pharmaceutically acceptable acid addition salt” as used herein means any nontoxic organic or inorganic salt of any base compounds. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
[0061] The term “pharmaceutically acceptable basic addition salt” as used herein means any nontoxic organic or inorganic base addition salt of any acid compounds or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.
[0062] The term “inorganic counter ion” represents an inorganic ion that accompanies an ionic species in order to maintain electric neutrality. An inorganic counter ion may represent an anion or cation. An inorganic counterion may accompany a free acid or base of a compound represented herein. An inorganic ion may form by a reaction of an inorganic base or inorganic acid and a compound described herein that possesses a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type.
[0063] The term “organic counter ion” represents an organic counter ion that accompanies an ionic species in order to maintain electric neutrality. The organic ion may represent an anion orAtty Docket No. 60247-442119 cation. An organic counter ion may accompany a free acid or base of a compound represented herein. An organic ion may form by a reaction of an organic base or organic acid and a compound described herein that possesses a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type.
[0064] Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, mal onates, succinates, suberates, sebacates, fumarates, maleates, butyne- 1,4-dioates, hexyne- 1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methyl sulfonates, propyl sulfonates, besylates, xylenesulfonates, naphthalene- 1 -sulfonates, naphthal ene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pa., 1985.
[0065] Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.
[0066] “Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the compound of the present disclosure. Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U.S. Pat. Nos. 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.Atty Docket No. 60247-442119 The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filter, diluent, excipient, solvent or encapsulating material useful for formulating a drug for medicinal or therapeutic use.
[0067] The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol / liter.
[0068] In treatment methods according to the disclosure, an “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in subjects needing such treatment. Effective amounts or doses of the compounds of the disclosure may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the infection, the subject’s health status, condition, and weight, and the judgment of the treating physician. An exemplary dose is in the range of about from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily. The total dosage may be given in single or divided dosage units (e.g., BID, TID, QID).
[0069] REPRESENTATIVE EMBODIMENTS
[0070] To address the challenges described above, this disclosure describes a biomimetic LNP platform. In some embodiments, the platform may include three particular aspects and variations thereof (1) Lipids extracted directly from mammalian cells (e.g., HEK-293, patient-derived blood / tissue), preserving native lipid signatures for reduced immunogenicity; (2) A pH-responsive PEI-amine conjugate, enabling stable nucleic acid binding while mitigating cytotoxicity through tunable ionizability; and (3) Optional integration of sub- 10 nm gold nanoparticles to enhance cellular uptake and enable theranostic applications. For example, the platform may include three particular aspects and variations thereof (1) Lipids extracted directly from mammalian cells (e.g., HEK-293, patient-derived blood / tissue) using sodium hypochlorite (NaOCl) pretreatment, preserving native lipid signatures for reduced immunogenicity; (2) A pH-responsive PEI-arginine conjugate synthesized via DMAP / DCC / NHS chemistry, enabling stable nucleic acid binding while mitigating cytotoxicity through tunable ionizability; and (3) Optional integration of sub- 10 nm gold nanoparticles to enhance cellular uptake and enable theranosticAtty Docket No. 60247-442119 applications. By leveraging cell-specific or autologous lipids, this platform may circumvent immune recognition barriers inherent to synthetic carriers, while the covalent conjugation of arginine to PEI provides pH-dependent charge modulation for endosomal escape. These advances are advantageous for immunocompromised populations (e.g., chemotherapy patients), where conventional LNP compositions risk triggering cytokine storms or rapid macrophage-mediated clearance.
[0071] The present disclosure describes a gene and drug delivery system comprising lipid nanoparticles (e.g., cell-derived LNPs) with an ionizable cationic polymer conjugates and optionally gold nanoparticles. In some embodiments, the ionizable cationic polymer may be advantageous for nucleic acid binding and for endosomal escape. The optional integrated gold nanoparticles may also enhance cellular uptake. These components can be used independently or synergistically depending on the application.
[0072] In some aspects, the present disclosure relates to a lipid nanoparticle (LNP) composition comprising a lipid-PEI nanoparticle comprising an oxidized lipid and polyethylene imine (PEI). In some embodiments, the PEI is electrostatically complexed to the lipid. In some embodiments, the PEI is covalently bonded to the lipid.
[0073] In some aspects, the present disclosure is related to a process for preparing an lipid nanoparticle (LNP) composition comprising a lipid-PEI nanoparticle, the process comprising:
[0074] (a) extracting lipids from a sample, thereby forming an extracted lipid nanoparticle; and (b) contacting the extracted lipid nanoparticle with a polyethylene imine polymer (PEI), thereby forming a lipid-PEI nanoparticle.
[0075] In some embodiments, the sample in step (a) is a patient-derived sample. For example, the sample may be a blood sample or a tissue sample (e.g., a tumor sample). The sample may be a cell population and may be prepared by culturing cells. In some embodiments, the cells are commercially available cells that have been cultured. In some embodiments, the cells are extracted from the patient who is then subsequently in receipt of a treatment, which may be called autologous lipids.
[0076] In some embodiments, step (a) comprises (i) contacting the lipids or the cell population with a solution comprising an oxidizing agent. Treating the lipids or cell population with an oxidizing agent may lyse the cells of the cell population to release the lipids. Lysing blood cells (e.g., erythrocytes, leukocytes), for example, may allow for the isolation of cell membrane- derived lipids, which more closely mimic the lipidome of cells, enhancing biocompatibility and delivery efficiency. The oxidizing agent may further oxidize the lipids (e.g., the lipids from the cell population or the lipids isolated from the blood sample). In some embodiments, the oxidizing agent is preferably sodium hypochlorite. In some embodiments, the concentration ofAtty Docket No. 60247-442119 sodium hypochlorite is about 2% to about 10%. In some embodiments, the concentration of the sodium hypochlorite is about 5%.
[0077] In some embodiments, the cell population comprises mammalian cells. In some embodiments, the cell population comprises patient-derived cells. For example, the cell population can be prepared by extracting cells from a patient and then culturing the cells. In some embodiments, the cell population is prepared from commercially available cells. For example, the cells can be HEK 293 cells. In some embodiments, the cell population comprises aortic smooth muscle cells, skin fibroblasts, lung mesenchymal cells, or any combination thereof, any of which may be patient-derived.
[0078] In some embodiments, the lipids are extracted from a blood sample (e.g., blood plasma or serum) from a patient. Lipids extracted directly from blood plasma or serum may also be referred to as circulating lipids. In some embodiments, the lipids (e.g., circulating lipids) can be extracted directly from the blood sample without lysing cells. In some embodiments, the method includes lysing blood cells (e.g., erythrocytes, leukocytes) to isolate cell membrane-derived lipids, as these lipid may more closely mimic the lipidome of cells, enhancing biocompatibility and delivery efficiency.
[0079] In some embodiments, step (a) comprises (ii) separating the lipids using methanol: chloroform: water phase separation. In some embodiments, the lipid is in the form of a lipid nanoparticle after the step of separating.
[0080] The extracted lipid may then be covalently bound to PEI (e.g., the PEI-ionizable amine such as arginine) or may be complexed (e.g., electrostatically complexed) and not covalently bound. In some embodiments, an electrostatic interaction is formed between the lipid nanoparticle (e.g., the extracted lipid nanoparticle) and the PEI in step (b). In some embodiments, covalent bond is formed between the lipid nanoparticle (e.g., the extracted lipid nanoparticle) and the PEI in step (b).
[0081] The lipid nanoparticle can be activated (e.g., step (a2) activating the extracted lipid nanoparticle from step (a)) thereby forming an activated lipid-nanoparticle. In some embodiments, step (a2) is performed by contacting the extracted lipid nanoparticle with a coupling agent (e.g., NHS). In some embodiments, step (a2) is performed before step (b).
[0082] In some embodiments, the activated lipid nanoparticle is contacted with an ionizable polymer (e.g., step (b)). In some embodiments, this forms a covalent bond when the nanoparticle is an activated lipid-nanoparticle. In some embodiments, an electrostatic interaction is formed if the lipid nanoparticle has not been activated (e.g., has not been activated according to step (a2)).
[0083] The ionizable polymer can be polyethylene imine (PEI). In some embodiments, the PEI is a branched PEI or linear PEI, preferably a branched PEI. In some embodiments, the PEI has aAtty Docket No. 60247-442119 molecular weight of about 500 Da to about 30 kDa, such as about 600 Da, about 2,000 Da, or about 25 kDa. In some embodiments, the PEI has a molecular weight of about 500 Da to about 1,000 Da, about 1,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, or about 20,000 Da to about 30,000 Da. In some embodiments, transfection efficiency and nucleic acid condensation capacity and cytotoxicity may be affected by the molecular weight of PEI. For example, a PEI having a higher molecular weight may provide for stronger DNA condensation, while a PEI having a lower molecular weight may provide for reduced toxicity.
[0084] In some embodiments, the PEI has a molecular weight of about 1,000 Da to about 30,000 Da, such as about 1,000 Da to about 20,000 Da. In some embodiments, a PEI having a molecular weight of about 1,000 Da to about 30,000 Da provides an advantageous transfection efficiency and balance between nucleic acid condensation capacity and cytotoxicity. In certain preferred embodiments, the PEI has a molecular weight of about 1,000 Da to about 5,000 Da, such as about 2 kDa. In some embodiments, a PEI having a molecular weight of about 1,000 Da to about 5,000 Da provides an advantageous transfection efficiency and balance between nucleic acid condensation capacity and cytotoxicity.
[0085] In some embodiments, the PEI has a molecular weight of at least about 20 kDa. For example, the PEI may have a molecular weight of about 20 kDa to about 30 kDa (e.g., about 25 kDa). In some embodiments, a PEI having a molecular weight of about 25 kDa provides an advantageous transfection efficiency and balance between nucleic acid condensation capacity and cytotoxicity.
[0086] The PEI can comprise an ionizable amine (e.g., arginine, histidine, or a combination thereof). For example, in some embodiments the PEI has been reacted with an ionizable amine (e.g., an activated ionizable amine) such that the PEI is amine-terminated (e.g., the PEI comprises arginines, histidines, or combinations thereof, coupled to the PEI polymer). In some embodiments, the PEI can be synthesized by chemically activating an amine (e.g., arginine or histidine) using 4-dimethylaminopyridine (DMAP), N,N'-dicyclohexylcarbodiimide (DCC), and N-hydroxysuccinimide (NHS) in chloroform and contacting PEI. The resulting PEI polymer can exhibit pH-responsive behavior and allow for efficient binding and protection of cargo (nucleic acids e.g., (DNA / mRNA)) while facilitating endosomal escape for enhanced intracellular delivery.
[0087] In some embodiments, the PEI comprises an ionizable amine, and has a ratio of PEI to ionizable amine of about 5:1 to about 1:5, such as about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1 :2, about 1 :3, about 1 :4, or about 1:5. For example, the ratio of PEI to ionizable amine may be about 2:1, about 1:1, or about 1:2. In some embodiments, the ratio of PEI to ionizableAtty Docket No. 60247-442119 amine is about 2:1 to about 1:5, such as about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, or about 1:5. In some embodiments, the ratio of PEI to ionizable amine is about 1:1 to about 1:5, such as about 1:1, about 1 :2, about 1 :3, about 1 :4, or about 1 :5. In certain preferred embodiments, the ratio of PEI to ionizable amine is about 1:1. In some embodiments, a PEI having a higher content of ionizable amine provides an advantageous transfection efficiency and cytotoxicity.
[0088] In some embodiments, the PEI comprises a hydrophobic agent. In some embodiments, the PEI comprises a hydrophobic agent but does not include arginine or histidine. In some embodiments, the hydrophobic agent is activated using an activating agent (e.g., DCC / NHS / DMAP), and reacted with PEI and forms a covalent bond. In some embodiments, the PEI comprises a hydrophobic agent and further includes an ionizable amine such as arginine or histidine. In some embodiments, the hydrophobic agent is activated using an activating agent (.e.g, DCC / NHS / DMAP), and reacted with PEI-ionizable amine (e.g., PEI-arginine) and forms a covalent bond. In some embodiments, the hydrophobic agent is preferably deoxycholic acid. The hydrophobic agent may increase the hydrophobicity of the PEI to increase the encapsulation of small molecule therapeutics (e.g., small molecule drugs). For example, the hydrophobic agent may improve nanoparticle-cell membrane interaction.
[0089] In some embodiments, the lipid-PEI nanoparticle has a ratio (w / w) of lipid to PEI of about 5:1 to about 1:5, such as about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 1 :3, about 1 :4, or about 1:5. In some embodiments, the ratio of lipid to PEI is about 5: 1 to about 1:1, such as about 5:1, about 4:1, about 3:1, about 2:1, or about 1:1. In some embodiments, the ratio of lipid to PEI is about 2: 1 to about 1:1, such as about 2:1 or about 1 : 1. In certain preferred embodiments, the ratio of lipid to PEI is about 2: 1. In some embodiments, it may be beneficial to modify the ratio of lipid to PEI to adjust the net charge of the LNP as needed for different cargoes or cell types.
[0090] In some embodiments, the lipid-PEI nanoparticle comprises additional lipid component. For example, the additional lipid component may be a sterol (e.g., cholesterol or deoxycholic acid), a neutral lipid (e.g., DOPE, DSPC), a PEGylated lipid (e.g., DOPE-PEG), or any combination thereof.
[0091] In some embodiments, the lipid-PEI nanoparticle comprises an antioxidant. In some embodiments, the antioxidant comprises glutathione, ascorbic acid, a-tocopherol, or any combination thereof. In some embodiments, an antioxidant, such as tocopherol intercalates into the lipid layer (e.g., bilayer) of the lipid-PEI nanoparticle via hydrophobic interactions. In some embodiments, it may be advantageous for the lipid-PEI nanoparticle to include an antioxidant, such as tocopherol, to increase biocompatibility, especially when LNPs are exposed to cells. For example, antioxidants may decrease toxicity and improve overall formulation biocompatibility.Atty Docket No. 60247-442119 In some embodiments, the disclosure relates to a lipid nanoparticle (LNP) composition comprising: a lipid-PEI nanoparticle comprising an oxidized lipid and a polyethylene imine (PEI).
[0092] In some embodiments, the LNP composition further comprises gold nanoparticles. The gold nanoparticles can have a diameter of about 5 nm to about 25 nm. In some embodiments, the gold nanoparticles may enhance cellular uptake of payloads. The gold nanoparticles can absorb light energy (e.g., from a near-infrared laser) to generate localized heat, thus allowing for photothermal tuning. This heat can be used to enhance drug / gene release from the LNP composition or to transiently increase cell membrane permeability, improving cargo delivery efficiency. The gold nanoparticles can act as contrast agents, allowing clinicians or researchers to track the location and distribution of the LNP compositions in real time using imaging techniques such as computed tomography (CT) scans or photoacoustic imaging. This may enable monitoring of therapeutic delivery in vivo. In some embodiments, gold nanoparticles can catalyze the aerobic oxidation of NADH to NAD+ in physiological conditions.
[0093] In some embodiments, the LNP composition further comprises an antioxidant. In some embodiments, the antioxidant comprises glutathione, ascorbic acid, a-tocopherol, or any combination thereof.
[0094] In some embodiments, the LNP composition further comprises a therapeutic agent. For example, the therapeutic agent may be a nucleic acid, a small molecule, or a combination thereof. In some embodiments, the LNP composition further comprises a drug, such as a small molecule.
[0095] The LNP compositions described herein are capable of interacting with (e.g., encapsulating or complexing with) a cargo, such as a nucleic acid (e.g., RNA or DNA) or a drug.
[0096] In certain embodiments, the nucleic acid is an RNA (e.g., an mRNA, a microRNA, antisense oligonucleotides, or an siRNA) or a DNA (e.g., an ssDNA, a dsDNA, or a complimentary coding DNA (cDNA), or a DNA plasmid (pDNA)). In certain preferred embodiments, the nucleic acid is an mRNA. In certain preferred embodiments, the nucleic acid is a circular RNA. In certain embodiments, the nucleic acid is a DNA plasmid (pDNA).
[0097] The LNP compositions herein are capable of interacting with (e.g., encapsulating or complexing with) a nucleic acid (e.g., an mRNA or a DNA plasmid). In some embodiments, the encapsulation efficiency is greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 95%, or greater than about 97%. In certain embodiments, the encapsulation efficiency is about 85% to about 95%.
[0098] In some embodiments, the nucleic acid is from about 10 bp to about 10,000 bp. In some embodiments, the nucleic acid is less than about 5,000 bp, less than about 3,000 bp, or less thanAtty Docket No. 60247-442119 about 2,500 bp. In some embodiments, the nucleic acid is about 500 bp to about 2,500 bp, about 500 bp to about 2,000 bp or about 1,000 bp to about 2,000 bp.
[0099] In certain embodiments, the ratio of LNP to nucleic acid is about 1:1 to about 25:1 by weight. For example, the ratio of LNP to nucleic acid may be about 1 : 1 to about 20: 1, about 1 : 1 to about 15:1, about 1 : 1 to about 10:1, about 1 : 1 to about 7 : 1 , or about 1 : 1 to about 5 : 1 by weight. In some embodiments, the ratio of LNP to nucleic acid is less than about 25:1, less than about 20:1, less than about 15:1, less than about 10:1, or less than about 7:1 by weight. In some embodiments, the ratio of LNP to nucleic acid is less than about 7:1, such as less than about 5:1. In some embodiments, the ratio of LNP to nucleic acid is about 1:1, about 2:1, about 3:1, about 4:1, about 5:l, about 6:1, about 7:l, about 10:1, about 15:1, about 20:1, or about 25:1 by weight. In certain embodiments, the ratio of LNP to nucleic acid is about 3:1 to about 7:1 (e.g., about 5:1) by weight. In certain embodiments, the ratio of LNP to nucleic acid is about 1:1 to about 5 : 1 by weight.
[0100] In certain embodiments, the transfection efficiency is at least about 30%, at least about 50%, or at least about 70% into cells, for example in mammalian cells. In certain embodiments, the transfection efficiency is about 50% to about 99%, about 60% to about 99%, about 70% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, or about 95% to about 99%. In certain embodiments, the transfection efficiency is about 70% to about 99% and the ratio of LNP to nucleic acid is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 10:1, about 15:1, or about 20:1 by weight. In some embodiments, the transfection efficiency is about 70% to about 99% and the ratio of LNP to mRNA is about 3:1, about 4:1, about 5:1, about 6:1, or about 7:1 by weight. In some embodiments, the transfection efficiency is about 70% to about 99% and the ratio of LNP to mRNA is about 1 : 1 to about 5: 1 by weight. In some embodiments, the transfection efficiency is about 90% to about 99% and the ratio of LNP to plasmid DNA is about 3:1, about 4:1, about 5:1, about 6:1, or about 7: 1 by weight. In some embodiments, the transfection efficiency is about 90% to about 99% and the ratio of LNP to plasmid DNA is about 1 : 1 to about 5: 1 by weight.
[0101] In some embodiments, the LNP composition has a particle size of about 10 nm to about 500 nm, such as about 50 nm to about 250 nm. In some embodiments, the LNP composition has a particle size of about 100 nm.
[0102] The LNP compositions described herein can be used for treating disease. For example, the LNP compositions may be able to deliver a nucleic acid (i.e., a payload) that provides a therapeutic benefit to a patient. In certain embodiments, the LNP compositions are able to deliver the nucleic acid to cells, such as HEK-293 cells, human dermal fibroblast cells, humanAtty Docket No. 60247-442119 pigment epithelial cells, or human aortic smooth muscle cells. The compositions described herein can be used for treating disease.
[0103] Those skilled in the art will recognize that the species listed or illustrated herein are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
[0104] Pharmaceutical Compositions
[0105] For treatment purposes, pharmaceutical compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients. A pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, antioxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents. In preferred embodiments, pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
[0106] Sterile compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
[0107] The pharmaceutical compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms. Pharmaceutical compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation. Preferably, the compositions are formulated for intravenous or oral administration.
[0108] For oral administration, the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily. Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate,Atty Docket No. 60247-442119 lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
[0109] Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
[0110] Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
[0111] For parenteral use, including intravenous, intramuscular, intraperitoneal, intranasal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multidose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 pg / kg / minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
[0112] For nasal, inhaled, or oral administration, the inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier. The inventive compositions may be formulated for rectal administration as a suppository.
[0113] For topical applications, the compounds and compositions of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topicalAtty Docket No. 60247-442119 administration. Additionally, the compounds and compositions of the present invention may be adapted for skin microinjection, a technique leveraging microneedles or intradermal delivery systems for targeted applications. For microinjection, the compositions can be formulated with reduced viscosity to ensure injectability through fine needles, while maintaining stability under mechanical stress. For topical administration, the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the agents of the invention may utilize a patch formulation to effect transdermal delivery.
[0114] As used herein, the terms “treat” or “treatment” encompass both “preventative” and “curative” treatment. “Preventative” treatment is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom. “Curative” treatment includes reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition. Thus, treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying systemic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
[0115] The term “subject” refers to a mammalian patient in need of such treatment, such as a human.
[0116] In the inhibitory methods of the invention, an “effective amount” means an amount sufficient to inhibit the target protein. Measuring such target modulation may be performed by routine analytical methods such as those described below. Such modulation is useful in a variety of settings, including in vitro assays.
[0117] In treatment methods according to the invention, an “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in subjects needing such treatment. Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the infection, the subject’s health status, condition, and weight, and the judgment of the treating physician. An exemplary dose is in the range of about from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily. The total dosage may be given in single or divided dosage units (e.g., BID, TID, QID).Atty Docket No. 60247-442119 Once improvement of the patient’s disease has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms. Patients may also require chronic treatment on a long-term basis.
[0118] In some aspects, the compounds and compositions described herein can be used to treat a disease, for example a genetic disorder, cancer, or a neurodegenerative disease. In some embodiments, the disease is a genetic disorder. In some embodiments, the disease is cancer. In some embodiments, the disease is a neurodegenerative disease.
[0119] In some aspects, the compounds and compositions described herein can be used to image a cell or a disease. In some embodiments, an LNP composition as described herein (e.g., an LNP composition comprising a gold nanoparticle) can be used to image a cell or a disease. In some embodiments, the cell is in vitro. In some embodiments, the cell is in vivo. The gold nanoparticles can act as contrast agents, allowing clinicians or researchers to track the location and distribution of the LNPs in real time using imaging techniques such as computed tomography (CT) scans or photoacoustic imaging. This enables precise monitoring of therapeutic delivery in vivo.
[0120] In some aspects, the compounds and compositions described herein can be used to transfect a cell. In some embodiments, the cell is in vitro. In some embodiments, the cell is in vivo.
[0121] Drug Combinations
[0122] The compounds and compositions described herein may be used in pharmaceutical compositions or methods in combination with one or more additional active ingredients in the treatment of the diseases and disorders described herein. The additional active ingredients can include target ligands (e.g., peptides) for cell-specific uptake, stealth agents (e.g., PEGylated lipids) to reduce immune clearance, or endosmotic agents (e.g., pH-responsive polymers) to augment endosomal escape. These components are distinct from the primary payload (e.g., mRNA, chemotherapeutics) and are engineered to optimize LNP performance. Additional active ingredients may include lipid components, such as sterols (e.g., cholesterol or deoxycholic acid), neutral / helper lipids (e.g., DOPE, DSPC), or pegylated lipids (e.g., DOPE-PEG). For example, sterols may improve LNP stability, neutral / helper lipids may enhance fusion and endosomalAtty Docket No. 60247-442119 escape, and PEGylated lipids may improve circulation time and reduce aggregation. Further additional active ingredients include other therapeutics or agents that mitigate adverse effects of therapies for the intended disease targets. Such combinations may serve to increase efficacy, ameliorate other disease symptoms, decrease one or more side effects, or decrease the required dose of an inventive compound. The additional active ingredients may be administered in a separate pharmaceutical composition from a compound of the present invention or may be included with a compound of the present invention in a single pharmaceutical composition. The additional active ingredients may be administered simultaneously with, prior to, or after administration of a compound of the present invention.
[0123] Combination agents include additional active ingredients are those that are known or discovered to be effective in treating the diseases and disorders described herein, including those active against another target associated with the disease. For example, compositions and formulations of the invention, as well as methods of treatment, can further comprise other drugs or pharmaceuticals, e.g., other active agents useful for treating or palliative for the target diseases or related symptoms or conditions. For treating cancer, compounds described herein can be combined with systemic chemotherapy (anthracyclines, taxanes, platinum-containing chemotherapeutic agents, alkylating agents, antimetabolites, etc.) radiation, and / or immunotherapy in addition to surgical tumor removal The pharmaceutical compositions described herein may additionally comprise one or more of such active agents, and methods of treatment may additionally comprise administering an effective amount of one or more of such active agents.
[0124] The compositions described herein may be advantageous for a variety of reasons, including:
[0125] 1. Lipids can be extracted from mammalian cells (e.g., HEK-293 or patient-derived blood samples). The extraction may occur through oxidation (e.g., by sodium hypochlorite (NaOCl) pretreatment). In some embodiments, the lipids are extracted from HEK-293 cells, which may provide several benefits. For example, HEK-293 cells rapidly proliferate and are scalable, which may enable a cost-effective production of lipids with biomimetic properties for broad research and industrial applications. Additional cell types, similar to the anticipated in vivo recipient cell, may also be used (aortic smooth muscle cells (SMC), skin fibroblasts, and lung mesenchymal cells are also available commercially to support this process). Use of such cell types may provide a lipid profile that is more similar to the native cells to which cargo delivery is intended, aiding integration. Further, patient-derived lipids (e.g., from blood samples) may also be incorporated. Autologous lipids may enhance biocompatibility and reduce immunogenicity by mimicking theAtty Docket No. 60247-442119 recipient’s native membrane composition. This approach minimizes immune recognition, an advantage for in vivo therapeutic applications.
[0126] 2. Second, the ionizable cationic polymer can be synthesized by chemically activating arginine using 4-dimethylaminopyridine (DMAP), N,N'-dicyclohexylcarbodiimide (DCC), and N-hydroxysuccinimide (NHS) in chloroform. These reagents enable covalent conjugation of arginine to polyethyleneimine (PEI): DMAP acts as a catalyst for carbodiimide-mediated coupling, DCC activates the carboxyl groups of arginine for reaction with PEI’s primary amines, and NHS stabilizes the reactive intermediate to improve conjugation efficiency. The resulting PEI-arginine polymer exhibits pH-responsive behavior, enabling efficient binding and protection of cargo (nucleic acids (DNA / mRNA)) while facilitating endosomal escape for enhanced intracellular delivery.
[0127] 3. Gold nanoparticles in the size range of 5-25 nm may be integrated into the LNP matrix, significantly boosting cellular uptake through improved membrane interaction and offering potential for photothermal tuning or diagnostic imaging. The gold nanoparticles can absorb light energy (e.g., from a near-infrared laser) to generate localized heat, thus allowing for photothermal tuning. This heat can be used to enhance drug / gene release from the LNPs or to transiently increase cell membrane permeability, improving cargo delivery efficiency. The gold nanoparticles can act as contrast agents, allowing clinicians or researchers to track the location and distribution of the LNPs in real time using imaging techniques such as computed tomography (CT) scans or photoacoustic imaging. This enables precise monitoring of therapeutic delivery in vivo.
[0128] As noted above, the present disclosure may provide two complementary aspects for lipid sourcing:
[0129] A) Cell type specific lipids (e.g., HEK-293 -derived lipids for targeting HEK-293 or aortic SMC for targeting SMCs). This method enables scalable batch production of LNPs tailored to specific tissues, leveraging shared lipid profiles across individuals for broader therapeutic applications. B) Patient-specific lipids (e.g., isolated from blood samples): While lipids are less immunogenic than proteins, recent studies demonstrate that synthetic or heterologous lipid formulations can still activate innate immune pathways (e.g., complement system, TLR4), which may interfere with therapeutic efficacy. Patient-derived lipids may decrease this risk by preserving native lipid signatures, offering a safety and efficacy benefit. By using lipids derived from the patient’s own cells (autologous lipids), the LNPs closely mimic the recipient’s native lipid composition. This minimizes immune recognition, thereby reducing two risks, even in immunocompromised patients:Atty Docket No. 60247-442119 (1) Immune-Mediated Clearance: Even weakened immune systems may retain residual activity (e.g., macrophages, complement proteins) that could attack synthetic or non-self lipids. Autologous lipids evade this detection, increasing the number of LNPs reaching target cells.
[0130] (2) Inflammatory Complications: Immunocompromised patients are highly vulnerable to cytokine storms or unintended immune activation. Avoiding foreign lipid-triggered TLR / NF-KB pathways may provide a safer delivery without exacerbating systemic inflammation.
[0131] This approach may be advantageous for immunocompromised populations (e.g., chemotherapy patients, HIV / AIDS, or primary immunodeficiency disorders), where conventional LNPs risk harmful immune reactions.
[0132] In some embodiments, the compositions may include a deoxycholic acid-modified PEI-Arginine in place of PEI / arginine to allow for encapsulation of hydrophobic drugs or hydrophilic small molecules.
[0133] In some embodiments, the LNP compositions described herein comprise cell-derived lipids conjugated with PEI-arginine. Gold nanoparticles and / or the deoxy cholic acid modification are modular additions tailored to specific therapeutic or diagnostic needs.
[0134] In some embodiments, advantageous transfection efficiency may be due to the combined nucleic acid condensing capability of PEI-arginine and the biomimetic lipid architecture, reduced immunogenicity from natural lipid sourcing, and dual utility for both gene therapies (e.g., nucleic acids) and drug delivery (e.g., chemotherapeutics). Furthermore, certain embodiments of patient-derived lipids may enable personalized therapeutic formulations tailored to individual cellular profiles. Applications include gene therapy for genetic disorders, cancer, and neurodegenerative diseases, as well as diagnostic imaging through gold nanoparticle-enabled tracking. By integrating cell-derived materials, tunable polymers, and functional nano-adjuvants, the compositions described herein may provide certain advantageous, for example a versatile, scalable advancement in targeted delivery systems with broad therapeutic and diagnostic potential.
[0135] In certain embodiments, the compositions described herein may provide the following features:
[0136] 1. Enhanced Biocompatibility: Cell-Derived Lipids: Designed to mimic host membrane composition, which may reduce immunogenicity risks compared to synthetic lipid carriers. PEL Arginine Conjugates: Engineered to mitigate cytotoxicity observed with unmodified PEI while retaining nucleic acid binding capacity. Certain results described herein (e.g., cell viability assessments during formulation testing) suggest these design features improve biocompatibility.Atty Docket No. 60247-442119 2. Increased Delivery Efficiency: Gold nanoparticles may enhance cellular uptake of payloads. pH-responsive PEI-arginine may be advantageous for endosomal escape and may improve intracellular nucleic acid release compared to non-ionizable cationic carriers.
[0137] 3. Synergistic Dual Personalized Medicine Pathways: Patient-Specific LNPs: Lipids isolated from autologous sources (e.g., patient blood samples) enable fully personalized formulations that mirror the recipient’s lipidome, minimizing immune rejection risks for high risk applications (e.g., chronic therapies). Cell Type-Specific LNPs: Lipids derived from specific cell types (e.g., HEK-293 for epithelial targeting, hepatocytes for liver targeting) allow ‘off-the-shelf batches tailored to tissues or diseases.
[0138] Synergy: In some cases, cell-type and patient specific strategies could be used simultaneously. For example, cells from an extracted tumor could be used to provide a lipome to better enable chemotherapy delivery to residual tumor cells. The combination would enable optimal cell-type specific docking of the LNP while minimizing immune response.
[0139] In certain embodiments, the compositions described herein provide the following features:
[0140] 1. Sodium Hypochlorite Pretreatment: May allow for efficient cell lysis and lipid extraction.
[0141] 2. PEI-Arginine Conjugate: DMAP / DCC / NHS chemistry to covalently link arginine to PEI, thereby creating a tunable ionizable cationic platform.
[0142] 3. Gold-Enhanced Hybrid LNPs: Integration of sub- 10 nm gold nanoparticles into cell-derived lipid / polymer systems to synergistically boost uptake and enable theranostic applications.
[0143] 4. Deoxycholic Acid Modification: A hydrophobic variant of PEI-arginine for stable encapsulation of small-molecule drugs.
[0144] In some embodiments, an LNP composition comprises an LNP with or without a gold nanoparticle as described herein and a nucleic acid (sometimes called a payload) complexed to the LNP. For example, the nucleic acid may be complexed to the LNP through electrostatic interactions. In certain preferred embodiments, the LNP of the composition serves as a transfection agent to deliver a nucleic acid to a cell.
[0145] ADDITIONAL EMBODIMENTS
[0146] Additional embodiments, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure. The compounds and compositions of the present disclosure can be described as embodiments in any of the following enumerated embodiments. It will be understood that any of the embodiments described hereinAtty Docket No. 60247-442119 can be used in connection with any other embodiments described herein to the extent that the embodiments do not contradict one another.
[0147] 1. A process for preparing a lipid nanoparticle (LNP) composition comprising a lipid-PEI nanoparticle, the process comprising:
[0148] (a) extracting lipids from a sample, thereby forming an extracted lipid nanoparticle; and (b) contacting the extracted lipid nanoparticle with a polyethylene imine polymer (PEI), thereby forming a lipid-PEI nanoparticle.
[0149] 2. The process of embodiment 1, wherein the sample in step (a) is a patient-derived sample.
[0150] 3. The process of embodiment 2, wherein the patient-derived sample is a blood sample or a tissue sample (e.g., a tumor sample).
[0151] 4. The process of any one of the preceding embodiments, wherein the sample in step (a) is a cell population.
[0152] 5. The process of embodiment 4, wherein the cell population is prepared by culturing cells.
[0153] 6. The process of any one of the preceding embodiments, wherein step (a) comprises (i) contacting the lipids or the cell population with a solution comprising an oxidizing agent (e.g., sodium hypochlorite) to lyse the cells of the cell population and to oxidize the lipids; and
[0154] (ii) separating the lipids using methanol: chloroform: water phase separation.
[0155] 7. The process of any one of embodiments 4-6, wherein the cell population comprises mammalian cells.
[0156] 8. The process of any one of embodiments 4-7, wherein the cell population comprises patient-derived cells.
[0157] 9. The process of any one of embodiments 4-8, wherein the cell population comprises aortic smooth muscle cells, skin fibroblasts, lung mesenchymal cells, erythrocytes, leukocytes, or any combination thereof.
[0158] 10. The process of any one of embodiments 4-7, wherein the cell population comprises HEK-293 cells.
[0159] 11. The process of any one of the preceding embodiments, wherein an electrostatic interaction is formed between the lipid nanoparticle and the PEI in step (b).
[0160] 12. The process of any one of embodiments 1-10, wherein the process comprises (a2) activating the extracted lipid nanoparticle from step (a), thereby forming an activated lipid nanoparticle, and wherein step (a2) occurs before step (b).
[0161] 13. The process of any one of the preceding embodiments, wherein step (a2) is performed by contacting the extracted lipid nanoparticle with a coupling agent (e.g., NHS).Atty Docket No. 60247-442119 14. The process of embodiment 12 or 13, wherein step (b) forms a covalent bond between the lipid nanoparticle and the PEI.
[0162] 15. The process of any one of the preceding embodiments, wherein the lipid-PEI nanoparticle comprises an antioxidant.
[0163] 16. The process of embodiment 15, wherein the antioxidant comprises glutathione, ascorbic acid, a-tocopherol, or any combination thereof.
[0164] 17. The process of any one of the preceding embodiments, further comprising combining the lipid-PEI nanoparticle with a gold nanoparticle.
[0165] 18. The process of embodiment 14, wherein the gold nanoparticle has a diameter of about 5 nm to about 25 nm.
[0166] 19. The process of any one of the preceding embodiments, wherein the PEI comprises an ionizable amine.
[0167] 20. The process of embodiment 16, wherein the ionizable amine comprises arginine, histidine, or a combination thereof.
[0168] 21. The process of any one of the preceding embodiments, further comprising complexing the lipid-PEI nanoparticle with a nucleic acid.
[0169] 22. The process of embodiment 21, wherein the nucleic acid is RNA (e.g., mRNA), DNA (e.g., plasmid DNA), or any combination thereof.
[0170] 23. The process of any one of the preceding embodiments, wherein the PEI comprises a hydrophobic agent (e.g., deoxycholic acid).
[0171] 24. The process of any one of the preceding embodiments, further comprising complexing the lipid-PEI nanoparticle with a drug.
[0172] 25. The process of embodiment 24, wherein the drug is a small molecule.
[0173] 26. An LNP composition made according to the process of any one of embodiments 1-25.
[0174] 27. A lipid nanoparticle (LNP) composition comprising:
[0175] a lipid-PEI nanoparticle comprising an oxidized lipid and polyethylene imine (PEI). 28. The LNP composition of embodiment 27, wherein the oxidized lipid is derived from mammalian cells.
[0176] 29. The LNP composition of embodiment 27 or 28, wherein the oxidized lipid is derived from a patient sample.
[0177] 30. The LNP composition of any one of embodiments 27-29, wherein the oxidized lipid is derived from cultured cells.
[0178] 31. The LNP composition of any one of embodiments 27-30, wherein the oxidized lipid is derived from kidney cells (e.g., HEK 293 cells), aortic SMC cells, skin fibroblasts, lung mesenchymal cells, hepatocytes, erythrocytes, leukocytes, or any combination thereof.Atty Docket No. 60247-442119 32. The LNP composition of any one of embodiments 27-31, wherein the PEI comprises an ionizable amine.
[0179] 33. The LNP composition of embodiment 32, wherein the ionizable amine comprises arginine, histidine, or a combination thereof.
[0180] 34. The LNP composition of any one of embodiments 27-33, wherein the PEI comprises a hydrophobic agent (e.g., deoxycholic acid).
[0181] 35. The LNP composition of any one of embodiments 27-34, further comprising an antioxidant.
[0182] 36. The LNP composition of embodiment 35, wherein the antioxidant comprises glutathione, ascorbic acid, a-tocopherol, or any combination thereof.
[0183] 37. The LNP composition of any one of embodiments 27-36, wherein the PEI is covalently coupled to the oxidized lipid.
[0184] 38. The LNP composition of any one of embodiments 27-36, wherein the PEI forms an electrostatic interaction with the oxidized lipid and is not covalently coupled to the oxidized lipid.
[0185] 39. The LNP composition of any one of embodiments 27-38, further comprising a gold nanoparticle.
[0186] 40. The LNP composition of embodiment 39, wherein the gold nanoparticle has a diameter of about 5 nm to about 25 nm.
[0187] 41. The LNP composition of any one of embodiments 27-40, further comprising a therapeutic agent.
[0188] 42. The LNP composition of embodiment 41, wherein the therapeutic agent is a nucleic acid, a small molecule, or a combination thereof.
[0189] 43. The LNP composition of embodiment 41, wherein the nucleic acid is RNA (e.g., mRNA) or DNA (e.g., plasmid DNA).
[0190] 44. A method of treating a disease (e.g., a cardiovascular disease, aging, a genetic disorder, cancer, or a neurodegenerative disease) in a patient in need thereof, the method comprising: administering a therapeutically effective amount of the composition according to any one of embodiments 41-43 or made according to the process any one of embodiments 21-25. 45. The method according to embodiment 44, wherein the patient is an immunocompromised patient (e.g., a chemotherapy patient, an HIV / AIDS patient, or a patient having a primary immunodeficiency disorder).
[0191] 46. A method of transfecting a cell, the method comprising:
[0192] contacting the cell with an effective amount of the composition according to any one of embodiments 41-43 or made according to the process of any one of embodiments 21-25.Atty Docket No. 60247-442119 47. The method of embodiment 46, wherein the step of contacting of the cell is performed in vitro.
[0193] 48. The method of embodiment 46, wherein the step of contacting of the cell is performed in vivo.
[0194] 49. A method of imaging a cell, the method comprising:
[0195] contacting the cell with an effective amount of a composition according to any one of embodiments 41-43 or made according to a process according to any one of embodiments 21-25.
[0196] 50. The method of embodiment 49, wherein the step of contacting of the cell is in vitro. 51. The method of embodiment 49, wherein the step of contacting of the cell is in vivo.
[0197] EXAMPLES
[0198] Exemplary chemical entities useful in methods of the description will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order that is compatible with the functionality of the particular pendant groups.
[0199] Abbreviations
[0200] The examples described herein use materials, including but not limited to, those described by the following abbreviations known to those skilled in the art:
[0201] g grams
[0202] eq equivalents
[0203] mmol millimoles
[0204] mL milliliters
[0205] pm micrometers
[0206] RT room temperature
[0207] °C degrees Celsius
[0208] min minutes
[0209] hr hours
[0210] M molar
[0211]
[0212] pM or uM micromolarAtty Docket No. 60247-442119 U / mL units of activity per milliliter
[0213] ICso Inhibitory concentration for half-maximal signal in biochemical assay EC50 Effective concentration for half-maximal signal in proliferation assays CC50 Cytotoxicity concentration for half-maximal signal in cell viability assays.
[0214]
[0215] ADME absorption, distribution, metabolism and elimination
[0216] Materials and Methods
[0217] Lipid nanoparticles (LNPs) were synthesized using the optimized protocol of lipid extraction from different biological materials, e.g., HEK-293 cells and primary dermal human fibroblasts. This protocol is as versatile to complex biological matrices, e.g., tissue materials, e.g., placental membranes like the amnion and chorion, and human blood. In cell culture HEK-293 cell lipid extraction, cells were centrifugalized at 5 minutes at 400 x g and double washed with phosphate-buffered saline (PBS, pH 7.4) to desiccate media components. Centrifugalized cells were treated using NaOCl solution (0.5%) in PBS and left at room temperature for 2 hours. This treatment allowed efficient cell lysis and oxidation of the lipids. For solid tissues, mechanical homogenization before treatment using NaOCl was performed to allow efficient disruption of the cell constructs. In case of liquid-liquid LNP extraction, methanol: chloroform: water mixture at ratio 1:1:1 was applied after treatment. After phase partitioning, the organic chloroform phase with extracted lipids was extracted using care, vacuum-dried, and redissolved using ethanol at 10 mg / mL. Lipids in ethanol were kept at -20°C until further processing.
[0218] In one example, polyethyleneimine (PEI, molecular weight 25 kDa), PEI-arginine, was prepared by covalent modification of branched PEI with L-arginine. Conjugation involved activating arginine (1 mmol) in chloroform under dry conditions by using the mixture of N,N'-dicyclohexylcarbodiimide (1.2 mmol), N-hydroxysuccinimide (1.5 mmol), and 4-dimethylaminopyridine (0.1 mmol) at 4°C for 2 hours. Activated arginine solution was then mixed with PEI under steady stir condition in chloroform for 18 hours at room temperature. Small molecules not reacting were removed by dialysis against PBS (pH 7.4) in 10 kDa molecular weight cut-off (MWCO) membrane for 48 hours. Final PEI-arginine conjugate was stored at -20°C. PEI-amino acid conjugates with PEI (molecular weight 2 kDa) and PEI (molecular weight 600 Da) were prepared using the above procedure and appropriate MWCO membranes.
[0219] Formulations of LNPs were prepared using the method of injecting ethanol. In one example, 10 mg of extracted lipids and 5 mg of PEI-arginine were mixed in ethanol. It was rapidly injected into a water solution of citrate buffered at pH 4.0 with nucleic acids such as plasmid DNA carrying GFP or mRNA carrying RFP. It was ensured to have a 3 : 1 volume ratio of ethanol and water and was mixed at 2,000 rpm for 5 minutes to enable the formation of the nanoparticles. It was left at 37°C for 30 minutes to stabilize the particles followed by dialysis against PBS for 8Atty Docket No. 60247-442119 hours to remove the ethanol. Final LNPs were sterilized using 0.22 gm syringe filters to obtain a homogenous set of the formed particles with particle size less than 220 nm. Transfection efficiency was tested in HEK-293 cells, human fibroblasts, and human smooth muscle cells from the aorta, seeded at 1 x 105cells into 24-well culture plates. Transfection was performed with 1-5 pg formulated nucleic acid in LNPs and left to culture for 48 hours. Transfection reporter gene expression (GFP or RFP) was visualized using fluorescence microscopy and measured using flow cytometry. Cytotoxicity was determined by trypan blue exclusion. Experiments were analyzed using Student's t-test or one-way ANOVA (GraphPad Prism 9), where p < 0.05 was considered significant.
[0220] Statistical Analysis:
[0221] The data were presented as mean ± SEM. Data were derived from at least three independent biological replicates. Statistical comparisons between multiple experimental groups were performed using one-way analysis of variance (ANOVA) and Tukey’s post-hoc test. GraphPad Prism (vl0.0.2) handled the stats and we flagged significance.
[0222] EXAMPLE 1
[0223] Lipid Nanoparticle (LNP) Extraction and Oxidation:
[0224] Lipid nanoparticles (LNPs) were purified from cell-derived lipid, such as HEK-293 cells or primary human dermal fibroblasts. In addition, this method can be applied to purify tissue-derived lipids such as placental amnion / chorion or blood, and hence flexibility is obtained in purifying LNPs from various biological systems.
[0225] Cell Processing:
[0226] The cells were centrifuged at 400 x g for 5 minutes, washed with phosphate-buffered saline twice at pH 7.4, and incubated with sodium hypochlorite at 0.5% at room temperature for 2 hours in order to oxidize lipids.
[0227] Tissue Processing:
[0228] Tissues such as placental amnion or chorion can be washed thoroughly and mechanically homogenized prior to NaOCl treatment under the same oxidative conditions as cells.
[0229] Blood Processing:
[0230] Whole blood samples can be centrifuged (2,000 x g, 10 min) to isolate the cellular fraction (buffy coat), followed by washing and NaOCl treatment to obtain oxidized lipid.Atty Docket No. 60247-442119
[0231] Lipid Extraction:
[0232] Lipids were purified after oxidation with the aid of the methanol: chloroform: water phaseseparation method in a volume / volume ratio of 1:1:1. Lipid-chloroform phase was separated, vacuum-dried, resuspended in ethanol concentrations of 10 mg / mL, and stored at -20°C.
[0233] General Procedure for the Preparation of Conjugated PEI-Amino Acids
[0234] The amino acid, such as histidine or arginine, was dissolved in water. The carboxyl group was activated using EDC / NHS for 15 minutes at room temperature. This activated amino acid solution was slowly added drop by drop to a solution of PEI (25 kDa, 2 kDa, or 600 Da) while stirring. The mixture was reacted for about 18 hours at room temperature. Ethanol was then added to precipitate the conjugated product after the reaction. The precipitate washed with additional ethanol to remove unreacted amino acids and coupling reagents. The purified conjugate was redissolved in water for storage and further use.
[0235] Synthesis of the Conjugated PEI-arginine:
[0236] Activation: Activation of L-arginine with chloroform with 1.2 mmol DCC, 1.5 mmol of NHS, and 0.1 mmol of DMAP at 4°C for 2 hours.
[0237] In one example, polyethyleneimine (PEI) with MW of 25 kDa was conjugated with the activated L-arginine under stirring at room temperature for 18 h in chloroform solution. Then, it was purified under dialysis against PBS MWCO of 10 kDa for a period of 48 h and -20°C. In another example, PEI with MW of 2 kDa was conjugated with activated L-arginine using similar methods and a MWCO of 1 kDa.
[0238] EXAMPLE 2
[0239] LNP Formulation:
[0240] Non-Covalent Assembly:
[0241] The PEI-Arginine (5 mg) and oxidized lipids (10 mg) was first dissolved in ethanol. The nucleic acid — either GFP / RFP plasmid DNA or the mRNA — were dissolved in phosphate buffer. Then the nucleic acid was combined with the ethanol solution of the LNP in various combinations: 1:1, 1 :2, or 1 :5 (i.e., the amount of nucleic acid to that of the LNP). On combining, the mixture was stirred thoroughly by shaking. It was then incubated at RT for half an hour so that nanoparticles would form. For the elimination of any leftover ingredients and the solvent, the formula was dialyzed against the solution of PBS with the pH of 7.4 for 8 hours. It was sterilized at the end with the help of filtering through the filter with pore size of 0.22 pm.Atty Docket No. 60247-442119 The particle size of compositions including lipid-PEI LNPs with complexed nucleic acid was characterized by dynamic light scattering (DLS). In one example, the mean size peak for a lipid-PEI-pDNA complex was approximately 100 nm.
[0242] Exemplary LNP formulations comprising non-covalently assembled PEI-Arginine / Histidine and oxidized lipids were prepared according to similar methods described above and shown in Table 1.
[0243] Table 1.
[0244] LNP No. Modified PEI PEI MW (kDa) PEI : Amine (w / w) Lipid : PEI (w / w) LNP1 PEI-Arginine 25 1 : 1 2 : 1 LNP2 PEI-Arginine 25 1 : 1 5 : 1 LNP3 PEI-Arginine 25 2 : 1 2 : 1 LNP4 PEI-Arginine 25 1 : 2 2 : 1 LNP5 PEI-Arginine 2 1 : 1 2 : 1 LNP6 PEI-Arginine 2 1 : 1 5 : 1 LNP7 PEI-Arginine 2 2 : 1 2 : 1 LNP8 PEI-Arginine 2 1 : 2 2 : 1 LNP9 PEI-Arginine 0.6 1 : 1 2 : 1 LNP 10 PEI-Histidine 25 1 : 1 2 : 1 LNP11 PEI-Histidine 2 1 : 1 2 : 1 LNP 12 PEI-Histidine 2 5 : 1 2 : 1 LNP13 PEI-Histidine 2 2 : 1 2 : 1 LNP 14 PEI-Histidine 2 1 : 2 2 : 1 LNP 15 PEI-Histidine 2 1 : 5 2 : 1 LNP 16 PEI-Histidine 2 1 : 1 5 : 1 LNP 17 PEI-Histidine 0.6 1 : 1 2 : 1 LNP 18 Non-Modified PEI 2 - 2 : 1
[0245]
[0246] Covalent Assembly (Amide-Linked LNPs):
[0247] Oxidized lipids or deoxy cholic acid (10 mg) were activated with DCC / NHS / DMAP in chloroform and subsequently reacted with PEI- Arginine (5 mg) for 24 hours at room temperature. The resulting conjugate was purified via dialysis and used for LNP formulation with nucleic acids as above.
[0248] Exemplary LNP formulations comprising covalently bound PEI-lipids were prepared and shown in Table 2.Atty Docket No. 60247-442119
[0249] Table 2.
[0250] LNP No. Conjugated Modified PEI MW PEI : Amine Lipid : PEI Lipid PEI (kDa) (w / w) (w / w) LNP21 Oxidized lipid PEI-Arginine 25 1 : 1 2 : 1 LNP22 Oxidized lipid PEI-Arginine 25 1 : 1 5 : 1 LNP23 Oxidized lipid PEI-Arginine 2 1 : 1 2 : 1 LNP24 Oxidized lipid PEI-Arginine 2 1 : 1 5 : 1 LNP25 Oxidized lipid PEI-Arginine 2 2 : 1 2 : 1 LNP26 Oxidized lipid PEI-Arginine 2 1 : 2 2 : 1 LNP27 Oxidized lipid PEI-Histidine 2 1 : 1 2 : 1 LNP28 Oxidized lipid PEI-Histidine 2 5 : 1 2 : 1 LNP29 Oxidized lipid PEI-Histidine 2 1 : 2 2 : 1 LNP30 Deoxy cholic PEI- Arginine 2 1 : 1 2 : 1 acid
[0251] LNP31 Deoxy cholic PEI-Arginine 2 1 : 1 5 : 1 acid
[0252] LNP32 Deoxy cholic PEI-Histidine 2 1 : 1 2 : 1
[0253]
[0254] acid
[0255] Gold Nanoparticle and Fluorescent Dye Integration:
[0256] Citrate-stabilized 10 nm gold nanoparticles (AuNPs) (5% w / w) and Alexa Fluor™ 555 dye (0.01% w / w) were co-encapsulated during LNP formation by adding them at the ethanol injection step. These labeled LNPs were used in cellular uptake analyses (Figs. 5A-B, 6).
[0257] Antioxidant Integration :
[0258] Additional Lipid-PEI nanoparticles were synthesized that incorporated tocopherol (an antioxidant). Tocopherol (5% w / w) was encapsulated during LNP formation by adding at the ethanol injection step.Atty Docket No. 60247-442119 EXAMPLE 3
[0259] Transfection and Cellular Analysis:
[0260] Cell Culture Methods:
[0261] The experiments utilized HEK-293 cells, primary human fibroblasts, aortic smooth muscle cells, and ARPE-19 retinal pigment epithelial cells. The cells received seeding at 1 x 105per well in 24-well plates with regular growth media specifically designed for each cell type.
[0262] All cultures grew under standard lab conditions at 37 °C, 5% CO2, in humid air. HEK293 cells and human dermal fibroblasts were kept in high-glucose DMEM supplemented with 10% FBS and 1% penicillin / streptomycin. As the cultures expand, each line was passaged at around 70-80% confluence. To achieve this, cells were detached using 0.25% trypsin-EDTA, which in turn allowed for efficient reseeding and continued proliferation. ARPE-19 cells preferred a 1:1 DMEM / Ham's F-12 mix (Gibco) with 10% FBS. Cells were kept between passages 20 and 35. As for HA-SMCs were cultured in Smooth Muscle Cell Basal Medium (Lonza), supplemented with supplemented with the SmGM®-2 SingleQuots® kit (Lonza, CC-4149). Experiments restricted cells to passages 4 through 10 to preserve the smooth muscle phenotype stability. Cells were ready for transfection when they reached a confluence of 70-80%. For each transfection experiment, LNPs were loaded with either 1 pg of plasmid DNA or 500 ng of mRNA per 106cells. The LNPs were added directly to the cells in culture medium, and cells were incubated under standard conditions for the duration required for the downstream assay.
[0263] Transfection Protocol: The cells received lipid nanoparticles containing GFP or RFP plasmid DNA or GFP mRNA through introduction at 1:1, 2:1 and 5:1 weight ratio of LNPs to nucleic acids. The transfected cells received standard culture conditions at 37 °C with 5% CO2 for 24 to 72 hours based on experimental requirements.
[0264] Fluorescence Microscopy:
[0265] Images were acquired using Zeiss or Nikon Eclipse Ti microscopes equipped with 20* or 40 x objectives:
[0266] GFP: Excitation / Emission = 488 / 510 nm
[0267] RFP: Excitation / Emission = 558 / 583 nm
[0268] Alexa Fluor™ 555: Excitation / Emission = 555 / 565 nm
[0269] Brightfield and fluorescent images were captured to assess transfection efficiency, LNP uptake, and cellular morphology (Figs. 2A, 3, 4A-B, 5A-B, 6).Atty Docket No. 60247-442119 Flow Cytometry:
[0270] Cells were harvested and resuspended in PBS. Viable populations were gated using FSC-A vs SSC-A dot plots. Fluorescent signal (FITC / PE channels) was recorded using Attune flow cytometers, analyzing 20,000 events per sample. GFP+ cells were quantified using histogram compared to untreated controls and commercial transfection reagents. Results are shown in Figs.
[0271] 2B-D for LNP6.
[0272] Trypan Blue Uptake:
[0273] Trypan blue is a non-toxic, membrane-impermeable dye widely regarded as a gold standard for assessing cell viability. It selectively enters and stains non-viable cells with compromised membranes, while viable cells exclude the dye, allowing for clear differentiation between live and dead populations (Fig. 7 — Right).
[0274] To evaluate the drug delivery capability of the lipid nanoparticle (LNP) system, 0.4% trypan blue was encapsulated into LNPs with PEI-arginine (LNP6). This formulation was applied to HEK-293 cells to assess uptake. Viable cells — confirmed by their adherence to the culture plate and intact morphology — internalized the encapsulated trypan blue without compromising membrane integrity (Fig. 7 — Left).
[0275] When live cells were exposed to the trypan blue-LNP complex with LNP 13 (Fig. 8), the complex rapidly penetrated the cells (within 1 minute). Importantly, the cells remained alive, as seen by their normal morphology and attachment to the plate. Inside the cells, the LNP-encapsulated trypan blue gave off a red fluorescent signal, while control cells (trypan blue alone) showed no signal.
[0276] These findings demonstrate that the LNP compositions described herein can successfully deliver otherwise membrane-impermeable agents into viable cells.
[0277] RFP plasmid DNA Uptake:
[0278] To evaluate the gene delivery capability of the lipid nanoparticle (LNP) system, RFP pDNA was encapsulated into LNPs conjugated with PEI-histidine at different ratios. These formulations were applied to HEK-293 cells to assess uptake.
[0279] Fig. 9 shows LNPs with PEI (2 kDa) (a positively charged component) conjugated with histidine (having an imidazole group) using EDC / NHS chemistry. Different PEI to imidazole ratios were tested (LNPs 11-15). At high PEI ratios, the LNPs carry a strong positive charge which shows an increase in toxicity after transfection. However, as the imidazole ratio increases, the particles gain more ionizable (pH sensitive) charge properties and a decrease in toxicity is observed. The merged, fluorescence (RFP), and bright-field images (10x magnification)Atty Docket No. 60247-442119 demonstrate this trend, and a region where charge and toxicity are optimally balanced, e.g., at PEEimidazole ratios of 1:1, 1:2, and 1:5.
[0280] Agarose gel electrophoresis:
[0281] To evaluate how well the lipid nanoparticles (LNPs) protect DNA, an agarose gel electrophoresis experiment was performed. DNA (500 ng per lane, 5 pL of 100 ng / pL stock) and LNPs (5 pg, 5 pL from a 1 mg / mL stock) were mixed at room temperature and then run on an agarose gel with ethidium bromide (EtBr). Free (naked) DNA, including the DNA ladder as control, migrates normally through the gel and is clearly stained by ethidium bromide (EtBr). Upon encapsulation with LNPs , DNA was shielded, preventing EtBr intercalation and resulting in a lack of visible fluorescence signal. The results shown in Fig. 10 demonstrate that the LNPs efficiently protect genetic material from exposure.
Claims
Atty Docket No. 60247-442119WHAT IS CLAIMED IS:
1. A process for preparing a lipid nanoparticle (LNP) composition comprising a lipid-PEI nanoparticle, the process comprising:(a) extracting lipids from a sample comprising a cell population; and(b) contacting the extracted lipids with a polyethylene imine polymer (PEI), thereby forming a lipid-PEI nanoparticle.
2. The process of claim 1, wherein the sample in step (a) is a patient-derived sample.
3. The process of claim 2, wherein the patient-derived sample is a blood sample or a tissue sample (e.g., a tumor sample).
4. The process of any one of the preceding claims, wherein step (a) comprises(i) contacting the sample with a solution comprising an oxidizing agent (e.g., sodium hypochlorite), thereby lysing and releasing the lipids from cells of the cell population and oxidizing the lipids; and(ii) separating the lipids using methanol: chloroform: water phase separation.
5. The process of any one of the preceding claims, wherein the cell population is prepared by culturing cells (e.g., mammalian cells, such as patient-derived cells).
6. The process of any one of the preceding claims wherein the cell population comprises mammalian cells.
7. The process of any one of the preceding claims, wherein the cell population comprises patient-derived cells.
8. The process of any one of the preceding claims, wherein the cell population comprises aortic smooth muscle cells, skin fibroblasts, lung mesenchymal cells, erythrocytes, leukocytes, or any combination thereof.
9. The process of any one of the preceding claims, wherein the cell population comprises HEK-293 cells.
10. The process of any one of the preceding claims, wherein an electrostatic interaction is formed between the lipids and the PEI in step (b).
11. The process of any one of claims 1-9, wherein the process comprises (a2) activating the lipids (i.e., extracted lipids) from step (a) and wherein step (a2) occurs before step (b).
12. The process of claim 11, wherein step (a2) is performed by contacting the lipids (i.e., extracted lipids) from step (a) with a coupling agent (e.g., NHS).Atty Docket No. 60247-442119 13. The process of claim 11 or 12, wherein step (b) forms a covalent bond between one or more lipid (i.e., of the extracted lipids) and the PEI.
14. The process of any one of the preceding claims, wherein the lipid-PEI nanoparticle comprises an antioxidant (e.g., glutathione, ascorbic acid, a-tocopherol, or any combination thereof).
15. The process of any one of the preceding claims, further comprising combining the lipid-PEI nanoparticle with a gold nanoparticle.
16. The process of claim 15, wherein the gold nanoparticle has a diameter of about 5 nm to about 25 nm.
17. The process of any one of the preceding claims, wherein the PEI has a molecular weight of about 500 Da to about 30,000 Da (e.g., about 500 Da to about 1,000 Da, about 1,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, or about 20,000 Da to about 30,000 Da).
18. The process of any one of the preceding claims, wherein the PEI comprises an ionizable amine.
19. The process of claim 18, wherein the ionizable amine comprises arginine, histidine, or a combination thereof.
20. The process of claim 18 or 19, wherein the PEI has a ratio (w / w) of PEI to an ionizable amine of about 5:1 to about 1:5.
21. The process of any one of the preceding claims, wherein the lipid-PEI nanoparticle has a ratio (w / w) of lipid to PEI of about 5: 1 to about 1:5.
22. The process of any one of the preceding claims, wherein the PEI further comprises a hydrophobic agent (e.g., deoxycholic acid).
23. The process of any one of the preceding claims, wherein step (b) comprises contacting the lipids (i.e., extracted lipids) with a polyethylene imine polymer (PEI) and an additional lipid component, thereby forming the lipid-PEI nanoparticle,wherein the additional lipid component is a sterol (e.g., cholesterol or deoxycholic acid), a neutral lipid (e.g., DOPE, DSPC), a PEGylated lipid (e.g., DOPE-PEG), or any combination thereof.
24. The process of any one of the preceding claims, further comprising complexing the lipid-PEI nanoparticle with a nucleic acid.
25. The process of claim 24, wherein the nucleic acid is RNA (e.g., mRNA), DNA (e.g., plasmid DNA), or any combination thereof.
26. The process of any one of the preceding claims, further comprising complexing the lipid-PEI nanoparticle with a drug.Atty Docket No. 60247-442119 27. The process of claim 26, wherein the drug is a small molecule.
28. A lipid nanoparticle (LNP) composition made according to the process of any one of claims 1-27.
29. A lipid nanoparticle (LNP) composition comprising:a lipid-PEI nanoparticle comprising an oxidized lipid and a polyethylene imine (PEI).
30. The LNP composition of claim 29, wherein the oxidized lipid is derived from mammalian cells.
31. The LNP composition of claim 29 or 30, wherein the oxidized lipid is derived from a patient sample (i.e., a patient-derived sample).
32. The LNP composition of any one of claims 29-31, wherein the oxidized lipid is derived from cultured cells.
33. The LNP composition of any one of claims 29-32, wherein the oxidized lipid is derived from kidney cells (e.g., HEK 293 cells), aortic SMC cells, skin fibroblasts, lung mesenchymal cells, hepatocytes, erythrocytes, leukocytes, or any combination thereof.
34. The LNP composition of any one of claims 29-33, wherein the PEI has a molecular weight of about 500 Da to about 30,000 Da (e.g., about 500 Da to about 1,000 Da, about 1,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, or about 20,000 Da to about 30,000 Da).
35. The LNP composition of any one of claims 29-34, wherein the PEI comprises an ionizable amine.
36. The LNP composition of claim 35, wherein the ionizable amine comprises arginine, histidine, or a combination thereof.
37. The LNP composition of claim 35 or 36, wherein the PEI has a ratio (w / w) of PEI to an ionizable amine of about 5:1 to about 1:5.
38. The LNP composition of any one of claims 29-37, wherein the lipid-PEI nanoparticle has a ratio (w / w) of oxidized lipid to PEI of about 5:1 to about 1:5.
39. The LNP composition of any one of claims 29-38, wherein the PEI comprises a hydrophobic agent (e.g., deoxycholic acid).
40. The LNP composition of any one of claims 29-39, further comprising an additional lipid component, wherein the additional lipid component is a sterol (e.g., cholesterol or deoxycholic acid), a neutral lipid (e.g., DOPE, DSPC), a PEGylated lipid (e.g., DOPE-PEG), or any combination thereof.
41. The LNP composition of any one of claims 29-40, further comprising an antioxidant (e.g., glutathione, ascorbic acid, a-tocopherol, or any combination thereof).Atty Docket No. 60247-442119 42. The LNP composition of any one of claims 29-41, wherein the PEI is covalently coupled to the oxidized lipid.
43. The LNP composition of any one of claims 29-41, wherein the PEI forms an electrostatic interaction with the oxidized lipid and is not covalently coupled to the oxidized lipid.
44. The LNP composition of any one of claims 29-43, further comprising a gold nanoparticle.
45. The LNP composition of claim 44, wherein the gold nanoparticle has a diameter of about 5 nm to about 25 nm.
46. The LNP composition of any one of claims 29-45, further comprising a therapeutic agent.
47. The LNP composition of claim 46, wherein the therapeutic agent is a nucleic acid, a small molecule, or a combination thereof.
48. The LNP composition of claim 47, wherein the nucleic acid is RNA (e.g., mRNA) or DNA (e.g., plasmid DNA).
49. The LNP composition of any one of claims 29-48, further comprising a drug.
50. The LNP composition of claim 49, wherein the drug is a small molecule.
51. A method of treating a disease (e.g., a cardiovascular disease, aging, a genetic disorder, cancer, or a neurodegenerative disease) in a patient in need thereof, the method comprising: administering a therapeutically effective amount of the composition according to any one of claims 46-50 or made according to the process any one of claims 24-27.
52. The method according to claim 51, wherein the patient is an immunocompromised patient (e.g., a chemotherapy patient, an HIV / AIDS patient, or a patient having a primary immunodeficiency disorder).
53. A method of transfecting a cell, the method comprising:contacting the cell with an effective amount of the composition according to any one of claims 46-50 or made according to the process of any one of claims 24-27.
54. The method of claim 53, wherein the step of contacting of the cell is performed in vitro.
55. The method of claim 53, wherein the step of contacting of the cell is performed in vivo.
56. A method of imaging a cell, the method comprising:contacting the cell with an effective amount of a composition according to any one of claims 46-50 or made according to a process according to any one of claims 24-27.
57. The method of claim 56, wherein the step of contacting of the cell is in vitro.
58. The method of claim 56, wherein the step of contacting of the cell is in vivo.
